Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).

The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

The Polish, prospective, multicenter, observational, cohort study designed to collect longitudinal data on the management and clinical outcomes of patients with gMG naive to complement inhibitors who received ravulizumab in the scope of routine clinical practice within the frames of National Drug Program (NDP) for up to 42 months (~ 6 months baseline and ~36 months follow-up).

Inclusion Criteria:

• Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland.
• Patients willing to participate in the study and signed Informed Consent Form (ICF).
• Vaccination against N. meningitidis

Exclusion Criteria:

• Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP.
• Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.